Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer’s Director Nominees

Rhea-AI Summary

News Market Reaction – SEER

-1.80%

-1.80% Session close to close

In the Jul 8 session, SEER declined 1.80%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The board’s letter centers on the July 28, 2026 meeting and urges support for its seven‑member slate...

Analysis

The board’s letter centers on the July 28, 2026 meeting and urges support for its seven‑member slate against the Radoff-JEC campaign, framing board continuity as critical while ongoing acquisition proposals and governance disputes remain key risks to monitor.

Key Figures

Annual meeting date: July 28, 2026 Record date: May 29, 2026 Director nominees: 7 nominees +1 more

4 metrics

Annual meeting date July 28, 2026 Scheduled date for Seer’s upcoming Annual Meeting of Stockholders

Record date May 29, 2026 Shareholders of record entitled to vote at the Annual Meeting

Director nominees 7 nominees Number of Seer director nominees the Board asks holders to support

Proxy phone line (877) 456-3524 Toll‑free number for stockholders needing assistance with voting

Historical Context

5 past events · Latest: Jul 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 06	Dissident response letter	Negative	+35.2%	Radoff-JEC Group responded to CEO Omid Farokhzad’s take‑private acquisition proposal.
Jul 06	Investor presentation	Positive	+35.2%	Company filed investor presentation highlighting momentum, commercial opportunity and value creation potential.
Jul 02	Acquisition proposal	Positive	+35.2%	Chair and CEO submitted unsolicited proposal to acquire all Class A shares with cash and CVRs.
Jul 01	Patent/legal update	Neutral	-1.8%	Company prevailed in a European patent opposition while U.S. ITC opened investigation into Nanomics.
Jun 29	Dissident presentation	Negative	+0.0%	Radoff-JEC Group released materials urging stockholders to vote for boardroom change at Seer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news tied to acquisition proposals and management’s strategic messaging often coincided with large positive moves, while dissident and mixed legal updates showed more inconsistent or muted follow‑through.

Key Terms

proxy card, proteomics, life sciences tools, capital allocation

4 terms

proxy card regulatory

"vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card"

A proxy card is a document that allows shareholders to give someone else the authority to vote on their behalf at a company’s meeting. Think of it as a permission slip that ensures a shareholder’s interests are represented even if they cannot attend in person. For investors, proxy cards are important because they influence company decisions and governance, giving them a way to participate indirectly.

proteomics medical

"pioneer the nascent space of proteomics using the Board’s decades of industry"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

life sciences tools medical

"guide a category-creating life sciences tools company"

Laboratory instruments, consumables, software and systems used to conduct biological and chemical research, run diagnostic tests, and support drug or device development. Like the tools and appliances in a kitchen that let chefs produce dishes, these products enable scientists to do experiments, analyze samples and scale workflows. Investors watch them because their sales reflect research activity, recurring consumable demand and adoption of new technologies, which affect revenue stability and growth potential.

capital allocation financial

"Proven capital allocation and governance judgment"

Capital allocation is the process of deciding how a company or individual uses their money to grow, pay bills, save, or invest. It matters because good decisions can help build wealth and ensure resources are used wisely, while poor choices can limit growth or cause financial problems. Think of it like managing your allowance—deciding whether to spend, save, or invest to meet your goals.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card

REDWOOD CITY, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”) today issued a letter to stockholders containing important information for shareholders to consider in connection with the Company’s upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on July 28, 2026. Stockholders as of May 29, 2026 will be entitled to vote at the Annual Meeting.

The Board recommends that stockholders vote “FOR” the election of Seer’s seven highly qualified nominees on the BLUE proxy card.

The full text of the letter follows:

Dear Fellow Seer Stockholder,

At our upcoming Annual Meeting of Stockholders on July 28, 2026, your vote is critical to the continued success of Seer.

Seer has a purpose-built Board of Directors with the expertise needed to guide a category-creating life sciences tools company. This Board is committed to overseeing our strategy to pioneer the nascent space of proteomics using the Board’s decades of industry knowledge and insight.

At the Annual Meeting, Bradley Radoff and Michael Torok are attempting to replace three of your Board’s sitting directors - Seer’s Co-Founder, CEO and Chair Omid Farokhzad, M.D., Terrance McGuire and Dipchand (Deep) Nishar - with candidates who bring no proteomics experience, no life sciences tools experience and no platform operating experience. Radoff and Torok have offered no plan to build Seer. Their only desire is to strip Seer of its cash. Additionally, their nominees raise serious concerns regarding independence and their ability to act in the best interests of all stockholders.

The Three Directors that Radoff and Torok Are Trying to Remove Are Critical to Seer’s Future

Omid Farokhzad, M.D. Co-Founder, CEO and Chair; Director since 2017 ✓ Scientific architect of the Proteograph® Product Suite ✓ Founder of multiple life sciences platform companies ✓ Author of 200+ scientific papers and inventor on 250+ patents ✓ Seer’s largest long-term stockholder, together with family entities	Terrance McGuire Founding Partner of Polaris Partners; Director since 2017 ✓ Decades of healthcare investing and company- building experience ✓ Proven capital allocation and governance judgment ✓ Investor in Seer at inception and again at Seer’s IPO ✓ One of Seer’s longest-term stockholders	Dipchand (Deep) Nishar Technology and Growth Leader; Director since 2021 ✓ Former Senior Managing Partner at SoftBank Vision Fund ✓ Former Managing Director at General Catalyst ✓ Former senior executive at LinkedIn and Google ✓ Deep capital markets, growth investing and corporate strategy expertise

Seer’s Nominees Have the Right Experience, Radoff and Torok’s Nominees Do Not

Critical Experience Needed at Seer	Seer’s Director Nominees	Radoff and Torok’s Nominees
Proteomics or adjacent scientific platform expertise	✓	X
Life sciences tools operating experience	✓	X
Experience scaling innovative technology platforms	✓	X
Public company governance experience relevant to Seer	✓	X
Capital allocation discipline	✓	X
Long-term alignment with Seer stockholders	✓	X
Direct role in building Seer’s strategy	✓	X

The Board thoughtfully evaluated the three director candidates identified by Radoff and Torok and unanimously determined that they lack the relevant skillsets, experience and independence required to oversee a complex proteomics company at a critical stage of its evolution in a nascent market. The Board also offered, in good faith, to interview these candidates. Radoff and Torok declined to make them available for customary interviews. Radoff and Torok’s actions demonstrate an unwillingness to work constructively with the Board, and we believe that their nominees would diminish the overall quality of our purpose-built Board.

The issue is not whether Radoff and Torok’s nominees have experience in other fields. The issue is whether they have the right experience for Seer. They do not.

Radoff and Torok are not merely proposing alternative directors. They are trying to install nominees who, in our view, appear selected to advance their short-term agenda.

Support Long-Term Value Creation, Vote “FOR” Seer Today

Do not let Radoff and Torok derail Seer’s progress by replacing three critical members of the Board as we continue to build a new market in deep, unbiased proteomics.

Protect the value of your investment and vote the BLUE proxy card today “FOR” Seer’s seven highly qualified director nominees:

Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D.

Thank you for your continued support of Seer.

Sincerely,
The Seer Board of Directors

If you have any questions or require any assistance with voting your shares,
please call:

Innisfree M&A Incorporated

Stockholders may call toll free: (877) 456-3524

Advisors

Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph^® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s plans, strategies, expectations, strategic opportunities, business objectives, research and development initiatives, and prospects. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449

Investor Contact:
Marissa Bych
investor@seer.bio